Quantum Discovery
Quantum Discovery Labs is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!
Quantum on Google+
tuberculosis Archive
-
![QP42 is the lead compound in its class, a novel anti-TB compound with a novel mechanism of action. The molecule is being developed by Quantum and is currently in preclinical [...]](http://q-pharm.com/wp-content/uploads/2010/12/chart_7.png "QP42 in-vitro efficacy summary (MDR, XDR strains, other drugs/drug candidates)")
QP42 in-vitro efficacy summary (MDR, XDR strains, other drugs/drug candidates)
Posted on December 21, 2010 | No CommentsQP42 is the lead compound in its class, a novel anti-TB compound with a novel mechanism of action. The molecule is being developed by Quantum and is currently in preclinical [...] -
![Evaluation of bactericidal activity (ability to cause the death of the microorganism) of the substance QP42 in vitro was determined in the automated system Bactec MGIT 960. The precipitate the [...]](http://q-pharm.com/wp-content/themes/arras-theme/images/thumbnail.png "Bactericidal activity study of the newest anti-tuberculosis compound QP-42 completed")
Bactericidal activity study of the newest anti-tuberculosis compound QP-42 completed
Posted on June 14, 2010 | No CommentsEvaluation of bactericidal activity (ability to cause the death of the microorganism) of the substance QP42 in vitro was determined in the automated system Bactec MGIT 960. The precipitate the [...] -
![The situation with drug resistant forms of tuberculosis (TB), aka MDR and XDR forms, remains increasingly troubling. XDR form was originally identified in 2006 and by now comprising up to [...]](http://q-pharm.com/wp-content/uploads/2010/06/tb.png "Quantum tests a novel targeted anti-tuberculosis compound")
Quantum tests a novel targeted anti-tuberculosis compound
Posted on June 5, 2010 | No CommentsThe situation with drug resistant forms of tuberculosis (TB), aka MDR and XDR forms, remains increasingly troubling. XDR form was originally identified in 2006 and by now comprising up to [...] -
ISTC/NIH-NIAID meeting, Moscow, 17.11.09
Posted on November 17, 2009 | No CommentsAs part of recent efforts to expand cooperation in health, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) is interested in learning more about the spectrum of biomedical [...]